Legend Biotech (LEGN) EBITDA Margin (2019 - 2025)
Legend Biotech (LEGN) reported EBITDA Margin of 6.43% for Q4 2025, up 3609.0% on a YoY basis from 0.17% in Q4 2024, and down 143.18% quarter-over-quarter from 14.9% in Q3 2025.
Legend Biotech (LEGN) EBITDA Margin (2019 - 2025) Analysis & Trends
Legend Biotech has reported EBITDA Margin for 7 years, with the latest figure at 6.43% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin rose 3609.0% year-over-year to 6.43%; the trailing twelve-month figure through Dec 2025 stood at 1.76% (up 1337.0% YoY), and the FY2025 full-year result was 13.27%, up 3607.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 6.43%, down from 14.9% in the prior quarter.
- The five-year high for EBITDA Margin was 395.35% in Q4 2022, with the low at 1515.42% in Q2 2022.
- Historically, EBITDA Margin has averaged 184.42% across 5 years, with a median of 60.01% in 2024.
- Annual changes were most pronounced in 2022 — EBITDA Margin plunged 105761 bps — and 2023, when it jumped 123437 bps.
- Legend Biotech's EBITDA Margin stood at 230.36% in 2021, then surged by 72 bps to 395.35% in 2022, then slumped by 75 bps to 100.0% in 2023, then tumbled by 143 bps to 42.52% in 2024, then soared by 85 bps to 6.43% in 2025.
- The last three EBITDA Margin figures came in at 6.43% (Q4 2025), 14.9% (Q3 2025), and 0.46% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 18.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.43% |
| Sep 30, 2025 | 14.90% |
| Jun 30, 2025 | 0.46% |
| Mar 31, 2025 | -20.60% |
| Dec 31, 2024 | -42.52% |
| Sep 30, 2024 | 39.59% |
| Jun 30, 2024 | 15.40% |
| Mar 31, 2024 | -114.68% |
| Dec 31, 2023 | 100.00% |
| Sep 30, 2023 | -85.87% |
| Jun 30, 2023 | -281.06% |
| Mar 31, 2023 | -271.34% |
| Dec 31, 2022 | 395.35% |
| Sep 30, 2022 | -325.80% |
| Jun 30, 2022 | -1,515.42% |
| Mar 31, 2022 | -77.49% |
| Dec 31, 2021 | 230.36% |
| Sep 30, 2021 | -726.03% |
| Jun 30, 2021 | -457.81% |
| Mar 31, 2021 | -559.49% |